Wells Fargo Maintains Equal-Weight on CRISPR Therapeutics, Lowers Price Target to $70
Benzinga Newsdesk 1 hour ago
Analyst RatingsNewsPrice Target
Wells Fargo analyst Yanan Zhu maintains CRISPR Therapeutics (NASDAQ:CRSP) with a Equal-Weight and lowers the price target from $75 to $70.
Wells Fargo analyst Yanan Zhu maintains CRISPR Therapeutics (NASDAQ:CRSP) with a Equal-Weight and lowers the price target from $75 to $70.